David Loomis Sells 1,919 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,919 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $19,074.86. Following the sale, the chief accounting officer directly owned 40,193 shares of the company’s stock, valued at $399,518.42. The trade was a 4.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arvinas Price Performance

ARVN traded up $0.30 during trading on Wednesday, hitting $9.87. 787,117 shares of the stock traded hands, compared to its average volume of 855,453. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $14.51. The firm has a market capitalization of $636.81 million, a P/E ratio of -7.71 and a beta of 1.79. The firm has a 50-day moving average of $11.21 and a 200 day moving average of $11.68.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.05. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business had revenue of $15.60 million during the quarter, compared to analyst estimates of $16.61 million. During the same period in the prior year, the business earned $1.14 EPS. The company’s revenue for the quarter was down 91.7% on a year-over-year basis. As a group, equities analysts predict that Arvinas, Inc. will post -3.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on ARVN. Zacks Research lowered shares of Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Wall Street Zen lowered shares of Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Citigroup upped their price objective on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Wedbush upped their price objective on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Finally, Truist Financial set a $10.00 price objective on shares of Arvinas in a report on Wednesday, March 18th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $15.14.

Arvinas News Summary

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, suggesting meaningful upside from current levels. BTIG raises Arvinas price target
• Positive Sentiment: Arvinas and Pfizer struck a licensing deal with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), bringing in $85 million upfront and transition payments plus up to $320 million in additional milestones and royalties. Arvinas and Pfizer deal with Rigel
• Positive Sentiment: The company said VEPPANU became the first FDA-approved PROTAC, which validates Arvinas’ drug-degradation platform and supports its pipeline story. Arvinas Q1 2026 results and corporate update
• Neutral Sentiment: First-quarter results were mixed: Arvinas reported a smaller-than-expected loss of $0.90 per share, but revenue of $15.6 million missed estimates and fell sharply from a year ago. Arvinas Q1 earnings report
• Neutral Sentiment: Investors are also watching pre-earnings commentary and transcript coverage, but these items appear more informational than market-moving on their own. Arvinas earnings call transcript
• Negative Sentiment: Despite the product and licensing progress, Arvinas remains unprofitable with weak revenue trends, which may temper enthusiasm for the stock’s longer-term fundamentals. Arvinas earnings expectations

Institutional Trading of Arvinas

A number of institutional investors and hedge funds have recently bought and sold shares of ARVN. AQR Capital Management LLC bought a new stake in Arvinas during the 1st quarter valued at about $727,000. Jacobs Levy Equity Management Inc. bought a new stake in Arvinas during the 1st quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after purchasing an additional 2,122 shares in the last quarter. Millennium Management LLC increased its stake in Arvinas by 208.4% during the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after purchasing an additional 885,483 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Arvinas by 108.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after purchasing an additional 469,394 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.